JPH0441149B2 - - Google Patents
Info
- Publication number
- JPH0441149B2 JPH0441149B2 JP59013442A JP1344284A JPH0441149B2 JP H0441149 B2 JPH0441149 B2 JP H0441149B2 JP 59013442 A JP59013442 A JP 59013442A JP 1344284 A JP1344284 A JP 1344284A JP H0441149 B2 JPH0441149 B2 JP H0441149B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- group
- spiro
- dione
- chroman
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 claims description 95
- -1 piperazino group Chemical group 0.000 claims description 44
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 33
- 150000003839 salts Chemical class 0.000 claims description 31
- 239000002253 acid Substances 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- YEGZRRJAGUJLDV-UHFFFAOYSA-N spiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione Chemical compound N1C(=O)NC(=O)C11C2=CC=CC=C2OCC1 YEGZRRJAGUJLDV-UHFFFAOYSA-N 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- 150000001469 hydantoins Chemical class 0.000 claims description 13
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 11
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 11
- PJHXQSZJHGJZCC-UHFFFAOYSA-N 6-fluoro-3'-[3-(4-hydroxypiperidin-1-yl)propyl]-2,2-dimethylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(F)=CC=C2OC(C)(C)CC1(C1=O)NC(=O)N1CCCN1CCC(O)CC1 PJHXQSZJHGJZCC-UHFFFAOYSA-N 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000003003 spiro group Chemical group 0.000 claims description 7
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- 229940053195 antiepileptics hydantoin derivative Drugs 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- COIFZWCCQVYCGR-UHFFFAOYSA-N 2,2-diethyl-6-fluoro-3'-[3-(4-hydroxypiperidin-1-yl)propyl]spiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(F)=CC=C2OC(CC)(CC)CC1(C1=O)NC(=O)N1CCCN1CCC(O)CC1 COIFZWCCQVYCGR-UHFFFAOYSA-N 0.000 claims description 2
- MZMGXBLTEYZCBY-UHFFFAOYSA-N 3'-[3-(4-hydroxypiperidin-1-yl)propyl]spiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C1CC(O)CCN1CCCN1C(=O)C2(C3=CC=CC=C3OCC2)NC1=O MZMGXBLTEYZCBY-UHFFFAOYSA-N 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- BJXACBUGKVECBM-UHFFFAOYSA-N [1-[3-(6-fluoro-2,2-dimethyl-2',5'-dioxospiro[3h-chromene-4,4'-imidazolidine]-1'-yl)propyl]piperidin-4-yl] acetate Chemical compound C1CC(OC(=O)C)CCN1CCCN1C(=O)C2(C3=CC(F)=CC=C3OC(C)(C)C2)NC1=O BJXACBUGKVECBM-UHFFFAOYSA-N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims 1
- 229940091173 hydantoin Drugs 0.000 claims 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 39
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 238000000034 method Methods 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 239000002904 solvent Substances 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 230000003288 anthiarrhythmic effect Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- 238000010992 reflux Methods 0.000 description 7
- 239000013076 target substance Substances 0.000 description 7
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 6
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 229940039750 aconitine Drugs 0.000 description 6
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 6
- 206010003119 arrhythmia Diseases 0.000 description 6
- 230000006793 arrhythmia Effects 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 229960001404 quinidine Drugs 0.000 description 5
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 235000011181 potassium carbonates Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 235000011121 sodium hydroxide Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- GHVZOJONCUEWAV-UHFFFAOYSA-N [K].CCO Chemical compound [K].CCO GHVZOJONCUEWAV-UHFFFAOYSA-N 0.000 description 3
- 230000036982 action potential Effects 0.000 description 3
- 125000005530 alkylenedioxy group Chemical group 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 231100000636 lethal dose Toxicity 0.000 description 3
- 231100000053 low toxicity Toxicity 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 3
- 229910000105 potassium hydride Inorganic materials 0.000 description 3
- 235000011118 potassium hydroxide Nutrition 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 2
- 206010047289 Ventricular extrasystoles Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002763 arrhythmic effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 229960001066 disopyramide Drugs 0.000 description 2
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 231100000816 toxic dose Toxicity 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 206010047302 ventricular tachycardia Diseases 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- HXPZVIYTFVBBAH-UHFFFAOYSA-N 2,2,6-trimethyl-3'-[3-(4-phenylpiperidin-1-yl)propyl]spiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(C)=CC=C2OC(C)(C)CC1(C1=O)NC(=O)N1CCCN(CC1)CCC1C1=CC=CC=C1 HXPZVIYTFVBBAH-UHFFFAOYSA-N 0.000 description 1
- JOVJUUUVMHJFIK-UHFFFAOYSA-N 2,2-dibutyl-3'-[3-(4-hydroxy-4-phenylpiperidin-1-yl)propyl]spiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC=CC=C2OC(CCCC)(CCCC)CC1(C1=O)NC(=O)N1CCCN(CC1)CCC1(O)C1=CC=CC=C1 JOVJUUUVMHJFIK-UHFFFAOYSA-N 0.000 description 1
- PNILSDLXIVZGEV-UHFFFAOYSA-N 2,2-dibutyl-3'-[3-(4-phenylpiperidin-1-yl)propyl]spiro[3H-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC=CC=C2OC(CCCC)(CCCC)CC1(C1=O)NC(=O)N1CCCN(CC1)CCC1C1=CC=CC=C1 PNILSDLXIVZGEV-UHFFFAOYSA-N 0.000 description 1
- WPTJZLDLCOUTMO-UHFFFAOYSA-N 2,2-dibutyl-6-chloro-3'-[3-(4-hydroxypiperidin-1-yl)propyl]spiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(Cl)=CC=C2OC(CCCC)(CCCC)CC1(C1=O)NC(=O)N1CCCN1CCC(O)CC1 WPTJZLDLCOUTMO-UHFFFAOYSA-N 0.000 description 1
- FTVVXOYAYBUYTI-UHFFFAOYSA-N 2,2-dibutyl-6-fluoro-3'-[3-(4-oxopiperidin-1-yl)propyl]spiro[3H-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(F)=CC=C2OC(CCCC)(CCCC)CC1(C1=O)NC(=O)N1CCCN1CCC(=O)CC1 FTVVXOYAYBUYTI-UHFFFAOYSA-N 0.000 description 1
- PJZZSKFHAMLNAZ-UHFFFAOYSA-N 2,2-diethyl-6-fluoro-3'-[4-(4-hydroxypiperidin-1-yl)butyl]spiro[3H-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(F)=CC=C2OC(CC)(CC)CC1(C1=O)NC(=O)N1CCCCN1CCC(O)CC1 PJZZSKFHAMLNAZ-UHFFFAOYSA-N 0.000 description 1
- KYEGFESINWGSLX-UHFFFAOYSA-N 2,6-dimethyl-3'-[3-(4-phenylpiperidin-1-yl)propyl]spiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(C)=CC=C2OC(C)CC1(C1=O)NC(=O)N1CCCN(CC1)CCC1C1=CC=CC=C1 KYEGFESINWGSLX-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- BVLPZBJYGHGHNG-UHFFFAOYSA-N 3'-(3-bromopropyl)-6-fluoro-2,2-dimethylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(F)=CC=C2OC(C)(C)CC21NC(=O)N(CCCBr)C2=O BVLPZBJYGHGHNG-UHFFFAOYSA-N 0.000 description 1
- UASKFOAUHMLHKW-UHFFFAOYSA-N 3'-[2-(diethylamino)ethyl]-6-fluoro-2,2-dimethylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound O=C1N(CCN(CC)CC)C(=O)NC11C2=CC(F)=CC=C2OC(C)(C)C1 UASKFOAUHMLHKW-UHFFFAOYSA-N 0.000 description 1
- OVSRYGIDSUVCNR-UHFFFAOYSA-N 3'-[2-(dimethylamino)ethyl]-6-fluoro-2-methylspiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(F)=CC=C2OC(C)CC21NC(=O)N(CCN(C)C)C2=O OVSRYGIDSUVCNR-UHFFFAOYSA-N 0.000 description 1
- NJTOFCWPTSEPCT-UHFFFAOYSA-N 3'-[2-[di(propan-2-yl)amino]ethyl]-6-fluoro-2,2-dimethylspiro[3H-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound O=C1N(CCN(C(C)C)C(C)C)C(=O)NC11C2=CC(F)=CC=C2OC(C)(C)C1 NJTOFCWPTSEPCT-UHFFFAOYSA-N 0.000 description 1
- CYXIYYWNEKINRA-UHFFFAOYSA-N 3'-[3-(3,4a,5,7,8,8a-hexahydro-2h-[1,4]dioxino[2,3-c]pyridin-6-yl)propyl]-6-fluoro-2,2-dimethylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(F)=CC=C2OC(C)(C)CC11C(=O)N(CCCN2CC3OCCOC3CC2)C(=O)N1 CYXIYYWNEKINRA-UHFFFAOYSA-N 0.000 description 1
- NHTFKZOTFCFITP-UHFFFAOYSA-N 3'-[3-(4-hydroxy-4-phenylpiperidin-1-yl)propyl]-7-methoxy-8-methylspiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione Chemical compound CC=1C(OC)=CC=C2C=1OCCC2(C1=O)NC(=O)N1CCCN(CC1)CCC1(O)C1=CC=CC=C1 NHTFKZOTFCFITP-UHFFFAOYSA-N 0.000 description 1
- LSTOKYRPZZYRLR-UHFFFAOYSA-N 3'-[3-(4-hydroxy-4-phenylpiperidin-1-yl)propyl]spiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C1CN(CCCN2C(C3(C4=CC=CC=C4OCC3)NC2=O)=O)CCC1(O)C1=CC=CC=C1 LSTOKYRPZZYRLR-UHFFFAOYSA-N 0.000 description 1
- IPLLTBBDGLGLKJ-UHFFFAOYSA-N 3'-[3-(4-hydroxypiperidin-1-yl)propyl]-2,2,6-trimethylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(C)=CC=C2OC(C)(C)CC1(C1=O)NC(=O)N1CCCN1CCC(O)CC1 IPLLTBBDGLGLKJ-UHFFFAOYSA-N 0.000 description 1
- DGAXLOYIVGKDQC-UHFFFAOYSA-N 3'-[3-(4-hydroxypiperidin-1-yl)propyl]-6-methoxy-2,2-dimethylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(OC)=CC=C2OC(C)(C)CC1(C1=O)NC(=O)N1CCCN1CCC(O)CC1 DGAXLOYIVGKDQC-UHFFFAOYSA-N 0.000 description 1
- KUWDQQHIPHKGAW-UHFFFAOYSA-N 3'-[3-(4-hydroxypiperidin-1-yl)propyl]-6-methoxyspiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(OC)=CC=C2OCCC1(C1=O)NC(=O)N1CCCN1CCC(O)CC1 KUWDQQHIPHKGAW-UHFFFAOYSA-N 0.000 description 1
- TWFOMOIKQKJYNJ-UHFFFAOYSA-N 3'-[3-(4-hydroxypiperidin-1-yl)propyl]-7-methoxy-2,2,8-trimethylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound CC=1C(OC)=CC=C2C=1OC(C)(C)CC2(C1=O)NC(=O)N1CCCN1CCC(O)CC1 TWFOMOIKQKJYNJ-UHFFFAOYSA-N 0.000 description 1
- QMSUBOAATBGLRE-UHFFFAOYSA-N 3'-[3-(diethylamino)propyl]-6-fluoro-2,2-dimethylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound O=C1N(CCCN(CC)CC)C(=O)NC11C2=CC(F)=CC=C2OC(C)(C)C1 QMSUBOAATBGLRE-UHFFFAOYSA-N 0.000 description 1
- OGOFUCYCZCBGRR-UHFFFAOYSA-N 3'-[3-(dimethylamino)propyl]-2,2,6-trimethylspiro[3H-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound O=C1N(CCCN(C)C)C(=O)NC11C2=CC(C)=CC=C2OC(C)(C)C1 OGOFUCYCZCBGRR-UHFFFAOYSA-N 0.000 description 1
- OFUIKUGWFRIITH-UHFFFAOYSA-N 3'-[3-(dimethylamino)propyl]-2,2-dimethyl-6-nitrospiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound O=C1N(CCCN(C)C)C(=O)NC11C2=CC([N+]([O-])=O)=CC=C2OC(C)(C)C1 OFUIKUGWFRIITH-UHFFFAOYSA-N 0.000 description 1
- WCPVCJOYHJWLTP-UHFFFAOYSA-N 3'-[3-(dimethylamino)propyl]-2,2-dimethylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound O=C1N(CCCN(C)C)C(=O)NC11C2=CC=CC=C2OC(C)(C)C1 WCPVCJOYHJWLTP-UHFFFAOYSA-N 0.000 description 1
- APWODPXODFICQL-UHFFFAOYSA-N 3'-[3-(dimethylamino)propyl]-6-fluoro-2,2-dimethyl-8-nitrospiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound O=C1N(CCCN(C)C)C(=O)NC11C2=CC(F)=CC([N+]([O-])=O)=C2OC(C)(C)C1 APWODPXODFICQL-UHFFFAOYSA-N 0.000 description 1
- QYARCXNMAYLCHJ-UHFFFAOYSA-N 3'-[3-(dimethylamino)propyl]-6-fluoro-2,2-dimethylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound O=C1N(CCCN(C)C)C(=O)NC11C2=CC(F)=CC=C2OC(C)(C)C1 QYARCXNMAYLCHJ-UHFFFAOYSA-N 0.000 description 1
- JSQYQQZNDMOBMH-UHFFFAOYSA-N 3'-[3-(dimethylamino)propyl]-6-fluoro-2-methylspiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(F)=CC=C2OC(C)CC21NC(=O)N(CCCN(C)C)C2=O JSQYQQZNDMOBMH-UHFFFAOYSA-N 0.000 description 1
- IBECEFOVJBOZFN-UHFFFAOYSA-N 3'-[3-(dimethylamino)propyl]-6-methoxy-2,2-dimethylspiro[3H-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(OC)=CC=C2OC(C)(C)CC21NC(=O)N(CCCN(C)C)C2=O IBECEFOVJBOZFN-UHFFFAOYSA-N 0.000 description 1
- GIJMIPTXMBJYIW-UHFFFAOYSA-N 3'-[3-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]propyl]-6-fluoro-2,2-dimethylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCN1C(=O)C2(C3=CC(F)=CC=C3OC(C)(C)C2)NC1=O GIJMIPTXMBJYIW-UHFFFAOYSA-N 0.000 description 1
- APSCVLLYWUMYEF-UHFFFAOYSA-N 3'-[3-[4-[(4-chlorophenyl)methoxy]piperidin-1-yl]propyl]-6-fluoro-2,2-dimethylspiro[3H-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(F)=CC=C2OC(C)(C)CC1(C1=O)NC(=O)N1CCCN(CC1)CCC1OCC1=CC=C(Cl)C=C1 APSCVLLYWUMYEF-UHFFFAOYSA-N 0.000 description 1
- NYAVMYOCRBLAQY-UHFFFAOYSA-N 3'-[3-[bis(2-hydroxyethyl)amino]propyl]-6-fluoro-2,2-dimethylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(F)=CC=C2OC(C)(C)CC21NC(=O)N(CCCN(CCO)CCO)C2=O NYAVMYOCRBLAQY-UHFFFAOYSA-N 0.000 description 1
- NYYRRBOMNHUCLB-UHFFFAOYSA-N 3-chloro-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCCl NYYRRBOMNHUCLB-UHFFFAOYSA-N 0.000 description 1
- IJQWPHVBDVAXDT-UHFFFAOYSA-N 6,8-dichloro-3'-[3-(4-hydroxypiperidin-1-yl)propyl]-2,2-dimethylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(Cl)=CC(Cl)=C2OC(C)(C)CC1(C1=O)NC(=O)N1CCCN1CCC(O)CC1 IJQWPHVBDVAXDT-UHFFFAOYSA-N 0.000 description 1
- IWRJEXZCTBHDSK-UHFFFAOYSA-N 6,8-dichloro-3'-[3-(4-hydroxypiperidin-1-yl)propyl]spiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C1CC(O)CCN1CCCN1C(=O)C2(C3=CC(Cl)=CC(Cl)=C3OCC2)NC1=O IWRJEXZCTBHDSK-UHFFFAOYSA-N 0.000 description 1
- CWXPWKSEBDSODS-UHFFFAOYSA-N 6,8-dichloro-3'-[4-(4-hydroxypiperidin-1-yl)butyl]spiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C1CC(O)CCN1CCCCN1C(=O)C2(C3=CC(Cl)=CC(Cl)=C3OCC2)NC1=O CWXPWKSEBDSODS-UHFFFAOYSA-N 0.000 description 1
- HMPLXTXBEGUOOS-UHFFFAOYSA-N 6-bromo-3'-[2-(4-hydroxypiperidin-1-yl)ethyl]-2,2-dimethylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(Br)=CC=C2OC(C)(C)CC1(C1=O)NC(=O)N1CCN1CCC(O)CC1 HMPLXTXBEGUOOS-UHFFFAOYSA-N 0.000 description 1
- VKCFLDKHCSLAIK-UHFFFAOYSA-N 6-bromo-3'-[3-(4-hydroxypiperidin-1-yl)propyl]spiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C1CC(O)CCN1CCCN1C(=O)C2(C3=CC(Br)=CC=C3OCC2)NC1=O VKCFLDKHCSLAIK-UHFFFAOYSA-N 0.000 description 1
- LPVQXQUVKIMYJA-UHFFFAOYSA-N 6-bromo-3'-[3-(dimethylamino)propyl]-2,2-dimethylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound O=C1N(CCCN(C)C)C(=O)NC11C2=CC(Br)=CC=C2OC(C)(C)C1 LPVQXQUVKIMYJA-UHFFFAOYSA-N 0.000 description 1
- CUMUUBIMEBFYKT-UHFFFAOYSA-N 6-chloro-2,2-diethyl-3'-[2-(4-hydroxypiperidin-1-yl)ethyl]spiro[3H-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(Cl)=CC=C2OC(CC)(CC)CC1(C1=O)NC(=O)N1CCN1CCC(O)CC1 CUMUUBIMEBFYKT-UHFFFAOYSA-N 0.000 description 1
- JUVUHDXYPPRGBK-UHFFFAOYSA-N 6-chloro-2,2-dimethyl-3'-[3-(4-phenylpiperidin-1-yl)propyl]spiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(Cl)=CC=C2OC(C)(C)CC1(C1=O)NC(=O)N1CCCN(CC1)CCC1C1=CC=CC=C1 JUVUHDXYPPRGBK-UHFFFAOYSA-N 0.000 description 1
- BYMSBNGKQTUJSP-UHFFFAOYSA-N 6-chloro-2,2-dimethyl-3'-[4-(4-phenylpiperidin-1-yl)butyl]spiro[3H-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(Cl)=CC=C2OC(C)(C)CC1(C1=O)NC(=O)N1CCCCN(CC1)CCC1C1=CC=CC=C1 BYMSBNGKQTUJSP-UHFFFAOYSA-N 0.000 description 1
- JKDLYOFURDHHSJ-UHFFFAOYSA-N 6-chloro-2-methyl-3'-[3-(4-phenylpiperidin-1-yl)propyl]spiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(Cl)=CC=C2OC(C)CC1(C1=O)NC(=O)N1CCCN(CC1)CCC1C1=CC=CC=C1 JKDLYOFURDHHSJ-UHFFFAOYSA-N 0.000 description 1
- DAHMFYWGIKBGCW-UHFFFAOYSA-N 6-chloro-3'-[2-(diethylamino)ethyl]-2-methylspiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione Chemical compound O=C1N(CCN(CC)CC)C(=O)NC11C2=CC(Cl)=CC=C2OC(C)C1 DAHMFYWGIKBGCW-UHFFFAOYSA-N 0.000 description 1
- OFQIZPULBQURTQ-UHFFFAOYSA-N 6-chloro-3'-[2-(dimethylamino)ethyl]-2-methylspiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(Cl)=CC=C2OC(C)CC21NC(=O)N(CCN(C)C)C2=O OFQIZPULBQURTQ-UHFFFAOYSA-N 0.000 description 1
- KZDWCLLTJAMLSX-UHFFFAOYSA-N 6-chloro-3'-[3-(4-ethoxypiperidin-1-yl)propyl]-2,2-dimethylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C1CC(OCC)CCN1CCCN1C(=O)C2(C3=CC(Cl)=CC=C3OC(C)(C)C2)NC1=O KZDWCLLTJAMLSX-UHFFFAOYSA-N 0.000 description 1
- NNWIKQXVLAOFHJ-UHFFFAOYSA-N 6-chloro-3'-[3-(4-hydroxy-4-phenylpiperidin-1-yl)propyl]-2,2-dimethylspiro[3H-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(Cl)=CC=C2OC(C)(C)CC1(C1=O)NC(=O)N1CCCN(CC1)CCC1(O)C1=CC=CC=C1 NNWIKQXVLAOFHJ-UHFFFAOYSA-N 0.000 description 1
- VBRHMHXCFWVHLG-UHFFFAOYSA-N 6-chloro-3'-[3-(4-hydroxy-4-phenylpiperidin-1-yl)propyl]-2-methylspiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(Cl)=CC=C2OC(C)CC1(C1=O)NC(=O)N1CCCN(CC1)CCC1(O)C1=CC=CC=C1 VBRHMHXCFWVHLG-UHFFFAOYSA-N 0.000 description 1
- VDDQRGRMFUGJDD-UHFFFAOYSA-N 6-chloro-3'-[3-(4-hydroxypiperidin-1-yl)propyl]-2,2-dimethylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(Cl)=CC=C2OC(C)(C)CC1(C1=O)NC(=O)N1CCCN1CCC(O)CC1 VDDQRGRMFUGJDD-UHFFFAOYSA-N 0.000 description 1
- BFWNYZYMJUALNX-UHFFFAOYSA-N 6-chloro-3'-[3-(4-phenylpiperidin-1-yl)propyl]spiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(Cl)=CC=C2OCCC1(C1=O)NC(=O)N1CCCN(CC1)CCC1C1=CC=CC=C1 BFWNYZYMJUALNX-UHFFFAOYSA-N 0.000 description 1
- UMVWDZGEIGBPBG-UHFFFAOYSA-N 6-chloro-3'-[3-(dimethylamino)propyl]-2,2-dihexylspiro[3H-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(Cl)=CC=C2OC(CCCCCC)(CCCCCC)CC21NC(=O)N(CCCN(C)C)C2=O UMVWDZGEIGBPBG-UHFFFAOYSA-N 0.000 description 1
- WYWWQUPSIQQHNC-UHFFFAOYSA-N 6-chloro-3'-[3-(dimethylamino)propyl]-2,2-dimethylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound O=C1N(CCCN(C)C)C(=O)NC11C2=CC(Cl)=CC=C2OC(C)(C)C1 WYWWQUPSIQQHNC-UHFFFAOYSA-N 0.000 description 1
- QBEPATXCGUVSMB-UHFFFAOYSA-N 6-chloro-3'-[3-(dimethylamino)propyl]-2-ethylspiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(Cl)=CC=C2OC(CC)CC21NC(=O)N(CCCN(C)C)C2=O QBEPATXCGUVSMB-UHFFFAOYSA-N 0.000 description 1
- HFWMEODIHDBGHY-UHFFFAOYSA-N 6-chloro-3'-[3-(dimethylamino)propyl]-2-hexylspiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(Cl)=CC=C2OC(CCCCCC)CC21NC(=O)N(CCCN(C)C)C2=O HFWMEODIHDBGHY-UHFFFAOYSA-N 0.000 description 1
- AQUNYHBANWPJOF-UHFFFAOYSA-N 6-chloro-3'-[3-(dimethylamino)propyl]-2-methylspiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(Cl)=CC=C2OC(C)CC21NC(=O)N(CCCN(C)C)C2=O AQUNYHBANWPJOF-UHFFFAOYSA-N 0.000 description 1
- OVXCNYYPCMKWHA-UHFFFAOYSA-N 6-chloro-3'-[3-(dimethylamino)propyl]spiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione Chemical compound O=C1N(CCCN(C)C)C(=O)NC11C2=CC(Cl)=CC=C2OCC1 OVXCNYYPCMKWHA-UHFFFAOYSA-N 0.000 description 1
- OCVNFFHRELONQF-UHFFFAOYSA-N 6-chloro-3'-[4-(4-hydroxypiperidin-1-yl)butyl]-2,2-dimethylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(Cl)=CC=C2OC(C)(C)CC1(C1=O)NC(=O)N1CCCCN1CCC(O)CC1 OCVNFFHRELONQF-UHFFFAOYSA-N 0.000 description 1
- DQXQOZJUYAVJDG-UHFFFAOYSA-N 6-chloro-3'-[5-(4-hydroxypiperidin-1-yl)pentyl]-2,2-dimethylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(Cl)=CC=C2OC(C)(C)CC1(C1=O)NC(=O)N1CCCCCN1CCC(O)CC1 DQXQOZJUYAVJDG-UHFFFAOYSA-N 0.000 description 1
- ZPHMHDSMPQRBGG-UHFFFAOYSA-N 6-fluoro-2,2-dimethyl-3'-[3-(4-oxopiperidin-1-yl)propyl]spiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(F)=CC=C2OC(C)(C)CC1(C1=O)NC(=O)N1CCCN1CCC(=O)CC1 ZPHMHDSMPQRBGG-UHFFFAOYSA-N 0.000 description 1
- ILXARZBHAOTOQA-UHFFFAOYSA-N 6-fluoro-2,2-dimethyl-3'-[3-(4-phenylpiperidin-1-yl)propyl]spiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(F)=CC=C2OC(C)(C)CC1(C1=O)NC(=O)N1CCCN(CC1)CCC1C1=CC=CC=C1 ILXARZBHAOTOQA-UHFFFAOYSA-N 0.000 description 1
- GPEHPAWVOZLSMJ-UHFFFAOYSA-N 6-fluoro-2,2-dimethyl-3'-[3-(4-propoxypiperidin-1-yl)propyl]spiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C1CC(OCCC)CCN1CCCN1C(=O)C2(C3=CC(F)=CC=C3OC(C)(C)C2)NC1=O GPEHPAWVOZLSMJ-UHFFFAOYSA-N 0.000 description 1
- IOVNCMMVDQQFJX-UHFFFAOYSA-N 6-fluoro-2,2-dimethyl-3'-[4-(4-phenylpiperidin-1-yl)butyl]spiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(F)=CC=C2OC(C)(C)CC1(C1=O)NC(=O)N1CCCCN(CC1)CCC1C1=CC=CC=C1 IOVNCMMVDQQFJX-UHFFFAOYSA-N 0.000 description 1
- DFENMZIPGYLPJT-UHFFFAOYSA-N 6-fluoro-2-methyl-3'-[3-(4-phenylpiperidin-1-yl)propyl]spiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(F)=CC=C2OC(C)CC1(C1=O)NC(=O)N1CCCN(CC1)CCC1C1=CC=CC=C1 DFENMZIPGYLPJT-UHFFFAOYSA-N 0.000 description 1
- FWLFQDSYNBYXBW-UHFFFAOYSA-N 6-fluoro-3'-[2-(4-hydroxypiperidin-1-yl)ethyl]-2,2-dimethylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(F)=CC=C2OC(C)(C)CC1(C1=O)NC(=O)N1CCN1CCC(O)CC1 FWLFQDSYNBYXBW-UHFFFAOYSA-N 0.000 description 1
- ZVUWHLXXLXUFQW-UHFFFAOYSA-N 6-fluoro-3'-[3-(3-hydroxypiperidin-1-yl)propyl]-2,2-dimethylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(F)=CC=C2OC(C)(C)CC1(C1=O)NC(=O)N1CCCN1CCCC(O)C1 ZVUWHLXXLXUFQW-UHFFFAOYSA-N 0.000 description 1
- MGCWJXGAASLGFM-UHFFFAOYSA-N 6-fluoro-3'-[3-(4-hydroxy-4-phenylpiperidin-1-yl)propyl]-2,2-dimethylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(F)=CC=C2OC(C)(C)CC1(C1=O)NC(=O)N1CCCN(CC1)CCC1(O)C1=CC=CC=C1 MGCWJXGAASLGFM-UHFFFAOYSA-N 0.000 description 1
- ZIIFHYAXPADACF-UHFFFAOYSA-N 6-fluoro-3'-[3-(4-hydroxypiperidin-1-yl)propyl]-2,2-dipropylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(F)=CC=C2OC(CCC)(CCC)CC1(C1=O)NC(=O)N1CCCN1CCC(O)CC1 ZIIFHYAXPADACF-UHFFFAOYSA-N 0.000 description 1
- JFLYZNXEERIVJQ-UHFFFAOYSA-N 6-fluoro-3'-[3-(4-methoxypiperidin-1-yl)propyl]-2,2-dimethylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C1CC(OC)CCN1CCCN1C(=O)C2(C3=CC(F)=CC=C3OC(C)(C)C2)NC1=O JFLYZNXEERIVJQ-UHFFFAOYSA-N 0.000 description 1
- NMENTYHCFYSZAX-UHFFFAOYSA-N 6-fluoro-3'-[3-(4-methoxypiperidin-1-yl)propyl]spiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C1CC(OC)CCN1CCCN1C(=O)C2(C3=CC(F)=CC=C3OCC2)NC1=O NMENTYHCFYSZAX-UHFFFAOYSA-N 0.000 description 1
- XJJDKHVBWMRXQK-UHFFFAOYSA-N 6-fluoro-3'-[4-(4-hydroxypiperidin-1-yl)butyl]-2,2-dimethylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(F)=CC=C2OC(C)(C)CC1(C1=O)NC(=O)N1CCCCN1CCC(O)CC1 XJJDKHVBWMRXQK-UHFFFAOYSA-N 0.000 description 1
- OOZCDGYNVWUZBH-UHFFFAOYSA-N 6-fluoro-3'-[4-(4-hydroxypiperidin-1-yl)butyl]-2,2-dimethylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione;hydrochloride Chemical compound Cl.C12=CC(F)=CC=C2OC(C)(C)CC1(C1=O)NC(=O)N1CCCCN1CCC(O)CC1 OOZCDGYNVWUZBH-UHFFFAOYSA-N 0.000 description 1
- SYHSZRAKKBMZII-UHFFFAOYSA-N 6-fluoro-3'-[5-(4-hydroxypiperidin-1-yl)pentyl]spiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C1CC(O)CCN1CCCCCN1C(=O)C2(C3=CC(F)=CC=C3OCC2)NC1=O SYHSZRAKKBMZII-UHFFFAOYSA-N 0.000 description 1
- UZEBXVJVJRYUQB-UHFFFAOYSA-N 6-fluoro-3'-[6-(4-hydroxypiperidin-1-yl)hexyl]-2,2-dimethylspiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(F)=CC=C2OC(C)(C)CC1(C1=O)NC(=O)N1CCCCCCN1CCC(O)CC1 UZEBXVJVJRYUQB-UHFFFAOYSA-N 0.000 description 1
- CHRDPIDXCRKXON-UHFFFAOYSA-N 6-methoxy-2,2-dimethyl-3'-[3-(4-phenylpiperidin-1-yl)propyl]spiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(OC)=CC=C2OC(C)(C)CC1(C1=O)NC(=O)N1CCCN(CC1)CCC1C1=CC=CC=C1 CHRDPIDXCRKXON-UHFFFAOYSA-N 0.000 description 1
- BHQZOBDVXMOSDC-UHFFFAOYSA-N 8-chloro-2,2-dimethyl-3'-[3-(4-phenylpiperidin-1-yl)propyl]spiro[3h-chromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC=CC(Cl)=C2OC(C)(C)CC1(C1=O)NC(=O)N1CCCN(CC1)CCC1C1=CC=CC=C1 BHQZOBDVXMOSDC-UHFFFAOYSA-N 0.000 description 1
- FWNGCIFRAVNPEQ-UHFFFAOYSA-N 8-chloro-3'-[3-(dimethylamino)propyl]spiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione Chemical compound O=C1N(CCCN(C)C)C(=O)NC11C2=CC=CC(Cl)=C2OCC1 FWNGCIFRAVNPEQ-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- DJIYNKJYKBHHFR-UHFFFAOYSA-N C(C)(C)C1=C(C(=NC=C1)NCC)C(C)C Chemical compound C(C)(C)C1=C(C(=NC=C1)NCC)C(C)C DJIYNKJYKBHHFR-UHFFFAOYSA-N 0.000 description 1
- CAQWNKXTMBFBGI-UHFFFAOYSA-N C.[Na] Chemical compound C.[Na] CAQWNKXTMBFBGI-UHFFFAOYSA-N 0.000 description 1
- VQSXUUWBSBGTBZ-UHFFFAOYSA-N C1CC(O)CCN1CCCN1C(=O)C2(C3=CC=CC(Cl)=C3OCC2)NC1=O Chemical compound C1CC(O)CCN1CCCN1C(=O)C2(C3=CC=CC(Cl)=C3OCC2)NC1=O VQSXUUWBSBGTBZ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042600 Supraventricular arrhythmias Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- OUEQLAHZQOXETB-UHFFFAOYSA-N [1-[2-(6-fluoro-2,2-dimethyl-2',5'-dioxospiro[3H-chromene-4,4'-imidazolidine]-1'-yl)ethyl]piperidin-4-yl] acetate Chemical compound C1CC(OC(=O)C)CCN1CCN1C(=O)C2(C3=CC(F)=CC=C3OC(C)(C)C2)NC1=O OUEQLAHZQOXETB-UHFFFAOYSA-N 0.000 description 1
- VMJQEFUOUYCEOO-UHFFFAOYSA-N [1-[3-(6-fluoro-2,2-dihexyl-2',5'-dioxospiro[3h-chromene-4,4'-imidazolidine]-1'-yl)propyl]piperidin-4-yl] acetate Chemical compound C12=CC(F)=CC=C2OC(CCCCCC)(CCCCCC)CC1(C1=O)NC(=O)N1CCCN1CCC(OC(C)=O)CC1 VMJQEFUOUYCEOO-UHFFFAOYSA-N 0.000 description 1
- NVAQDFCZWPOTDP-UHFFFAOYSA-N [1-[3-(6-methoxy-2,2-dimethyl-2',5'-dioxospiro[3h-chromene-4,4'-imidazolidine]-1'-yl)propyl]piperidin-4-yl] acetate Chemical compound C12=CC(OC)=CC=C2OC(C)(C)CC1(C1=O)NC(=O)N1CCCN1CCC(OC(C)=O)CC1 NVAQDFCZWPOTDP-UHFFFAOYSA-N 0.000 description 1
- MTJPCAZKJVZHIM-UHFFFAOYSA-N [1-[3-(8-chloro-2',5'-dioxospiro[2,3-dihydrochromene-4,4'-imidazolidine]-1'-yl)propyl]piperidin-4-yl] acetate Chemical compound C1CC(OC(=O)C)CCN1CCCN1C(=O)C2(C3=CC=CC(Cl)=C3OCC2)NC1=O MTJPCAZKJVZHIM-UHFFFAOYSA-N 0.000 description 1
- XKVVDENDYLQTDJ-UHFFFAOYSA-N [1-[4-(6-chloro-2',5'-dioxospiro[2,3-dihydrochromene-4,4'-imidazolidine]-1'-yl)butyl]piperidin-4-yl] acetate Chemical compound C1CC(OC(=O)C)CCN1CCCCN1C(=O)C2(C3=CC(Cl)=CC=C3OCC2)NC1=O XKVVDENDYLQTDJ-UHFFFAOYSA-N 0.000 description 1
- XKMVANCEEBDCOI-UHFFFAOYSA-N [1-[4-(6-fluoro-2,2-dimethyl-2',5'-dioxospiro[3H-chromene-4,4'-imidazolidine]-1'-yl)butyl]piperidin-4-yl] acetate Chemical compound C1CC(OC(=O)C)CCN1CCCCN1C(=O)C2(C3=CC(F)=CC=C3OC(C)(C)C2)NC1=O XKMVANCEEBDCOI-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- FHHZOYXKOICLGH-UHFFFAOYSA-N dichloromethane;ethanol Chemical compound CCO.ClCCl FHHZOYXKOICLGH-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Priority Applications (26)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59013442A JPS60158190A (ja) | 1984-01-30 | 1984-01-30 | ヒダントイン誘導体およびその製法ならびにそれを含有する医薬 |
| IE850136A IE850136L (en) | 1984-01-30 | 1985-01-22 | Hydantoin derivatives |
| PH31760A PH21920A (en) | 1984-01-30 | 1985-01-23 | Hydantoin derivatives and medicine containing the same |
| FI850302A FI83873C (fi) | 1984-01-30 | 1985-01-23 | Foerfarande foer framstaellning av hydantoinderivat foer anvaendning som laekemedel. |
| AU38062/85A AU585207B2 (en) | 1984-01-30 | 1985-01-24 | Hydantoin derivatives, process for producing the same and medicine containing the same. |
| US06/695,152 US4650798A (en) | 1984-01-30 | 1985-01-25 | Antiarrhythmic 2,2-dialkyl-1-(aminoalkyl)-spiro[chroman-4,4'-imidazolidine]-2',5'-diones |
| CH375/85A CH662354A5 (fr) | 1984-01-30 | 1985-01-28 | Derives de l'hydantoine, procede pour leur preparation et medicament contenant ces derives. |
| SE8500387A SE462849B (sv) | 1984-01-30 | 1985-01-28 | Hydantoinderivat, foerfarande foer framstaellning daerav samt farmaceutiska kompositioner innehaallande desamma |
| ZA85655A ZA85655B (en) | 1984-01-30 | 1985-01-28 | Hydantoin derivatives,process for producing the same and medicine containing the same |
| CA000472972A CA1249271A (en) | 1984-01-30 | 1985-01-28 | Hydantoin derivatives, process for producing the same and medicine containing the same |
| MX8350A MX160579A (es) | 1984-01-30 | 1985-01-28 | Procedimiento para producir derivados de hidantoina |
| NL8500248A NL8500248A (nl) | 1984-01-30 | 1985-01-29 | Hydantoinederivaten, werkwijze voor het bereiden daarvan, en een geneesmiddel dat dit bevat. |
| BE2/60602A BE901591A (fr) | 1984-01-30 | 1985-01-29 | Derives de l'hydantoine, procede de fabrication de ceux-ci et medicaments les contenant. |
| SU853856860A SU1468424A3 (ru) | 1984-01-30 | 1985-01-29 | Способ получени производных гидантоина |
| KR1019850000539A KR870001681B1 (ko) | 1984-01-30 | 1985-01-29 | 히단토인 유도체의 제조방법 |
| ES539942A ES8605523A1 (es) | 1984-01-30 | 1985-01-29 | Un procedimiento para la preparacion de derivados de hidantoina. |
| DK039585A DK158668C (da) | 1984-01-30 | 1985-01-29 | Hydantoinderivater, medikament indeholdende et saadant derivat, og anvendelse af et saadant derivat til fremstilling af et antiarrhytmisk medikament |
| HU85323A HU194885B (en) | 1984-01-30 | 1985-01-29 | Process for producing spirochroman-imidazolidine derivatives and pharmaceutical compositions containing them |
| NZ210979A NZ210979A (en) | 1984-01-30 | 1985-01-29 | Hydantoin derivatives and pharmaceutical compositions |
| IT19296/85A IT1184144B (it) | 1984-01-30 | 1985-01-30 | Derivati della idantoina,procedimento per la fabbricazione degli stessi e sostanza medicinale contenente i medesimi |
| DE19853503074 DE3503074A1 (de) | 1984-01-30 | 1985-01-30 | Hydantoinderivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten |
| FR858501296A FR2558835B1 (fr) | 1984-01-30 | 1985-01-30 | Derives d'hydantoine, leur procede de production et medicament les contenant |
| GB08502308A GB2155466B (en) | 1984-01-30 | 1985-01-30 | Hydantoin derivatives |
| ES548960A ES8606293A1 (es) | 1984-01-30 | 1985-11-15 | Un procedimiento para la preparacion de derivados de hidan- toina |
| SU864027225A SU1445559A3 (ru) | 1984-01-30 | 1986-04-02 | Способ получени производных гидантоина |
| SU864027211A SU1609453A3 (ru) | 1984-01-30 | 1986-04-02 | Способ получени производных гидантоина |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59013442A JPS60158190A (ja) | 1984-01-30 | 1984-01-30 | ヒダントイン誘導体およびその製法ならびにそれを含有する医薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60158190A JPS60158190A (ja) | 1985-08-19 |
| JPH0441149B2 true JPH0441149B2 (US20030186963A1-20031002-C00002.png) | 1992-07-07 |
Family
ID=11833246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59013442A Granted JPS60158190A (ja) | 1984-01-30 | 1984-01-30 | ヒダントイン誘導体およびその製法ならびにそれを含有する医薬 |
Country Status (23)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2708507B2 (ja) * | 1988-04-07 | 1998-02-04 | 株式会社三和化学研究所 | （ｄ）‐６‐フルオロ‐２，３‐ジヒドロ‐２’，５’‐ジオキソ‐スピロ［４Ｈ‐１‐ベンゾピラン‐４，４’‐イミダゾリジン］‐２‐カルボキサミド誘導体、これらの製法及び用途 |
| EP0347733A1 (en) * | 1988-06-20 | 1989-12-27 | Eisai Co., Ltd. | Optically active hydantoin derivatives |
| IL96507A0 (en) * | 1989-12-08 | 1991-08-16 | Merck & Co Inc | Nitrogen-containing spirocycles and pharmaceutical compositions containing them |
| US5206240A (en) * | 1989-12-08 | 1993-04-27 | Merck & Co., Inc. | Nitrogen-containing spirocycles |
| US5382587A (en) * | 1993-06-30 | 1995-01-17 | Merck & Co., Inc. | Spirocycles |
| US5403846A (en) * | 1993-11-22 | 1995-04-04 | Merck & Co., Inc. | Spirocycles |
| US5439914A (en) * | 1994-02-18 | 1995-08-08 | Merck & Co., Inc. | Spirocycles |
| GB2355264A (en) * | 1999-09-30 | 2001-04-18 | Merck & Co Inc | Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2455046A1 (fr) * | 1979-04-25 | 1980-11-21 | Science Union & Cie | Nouvelles hydantoines, leur procede de preparation et leur emploi comme medicament |
-
1984
- 1984-01-30 JP JP59013442A patent/JPS60158190A/ja active Granted
-
1985
- 1985-01-22 IE IE850136A patent/IE850136L/xx unknown
- 1985-01-23 PH PH31760A patent/PH21920A/en unknown
- 1985-01-23 FI FI850302A patent/FI83873C/fi not_active Application Discontinuation
- 1985-01-24 AU AU38062/85A patent/AU585207B2/en not_active Ceased
- 1985-01-25 US US06/695,152 patent/US4650798A/en not_active Expired - Fee Related
- 1985-01-28 MX MX8350A patent/MX160579A/es unknown
- 1985-01-28 ZA ZA85655A patent/ZA85655B/xx unknown
- 1985-01-28 CH CH375/85A patent/CH662354A5/fr not_active IP Right Cessation
- 1985-01-28 SE SE8500387A patent/SE462849B/sv not_active IP Right Cessation
- 1985-01-28 CA CA000472972A patent/CA1249271A/en not_active Expired
- 1985-01-29 ES ES539942A patent/ES8605523A1/es not_active Expired
- 1985-01-29 BE BE2/60602A patent/BE901591A/fr not_active IP Right Cessation
- 1985-01-29 KR KR1019850000539A patent/KR870001681B1/ko not_active IP Right Cessation
- 1985-01-29 HU HU85323A patent/HU194885B/hu not_active IP Right Cessation
- 1985-01-29 NL NL8500248A patent/NL8500248A/xx not_active Application Discontinuation
- 1985-01-29 DK DK039585A patent/DK158668C/da not_active IP Right Cessation
- 1985-01-29 SU SU853856860A patent/SU1468424A3/ru active
- 1985-01-29 NZ NZ210979A patent/NZ210979A/en unknown
- 1985-01-30 IT IT19296/85A patent/IT1184144B/it active
- 1985-01-30 FR FR858501296A patent/FR2558835B1/fr not_active Expired - Fee Related
- 1985-01-30 GB GB08502308A patent/GB2155466B/en not_active Expired
- 1985-01-30 DE DE19853503074 patent/DE3503074A1/de not_active Withdrawn
- 1985-11-15 ES ES548960A patent/ES8606293A1/es not_active Expired
-
1986
- 1986-04-02 SU SU864027225A patent/SU1445559A3/ru active
- 1986-04-02 SU SU864027211A patent/SU1609453A3/ru active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2139867C1 (ru) | Новые 4-арилпиперазины и 4-арилпиперидины, фармацевтическая композиция, способ ингибирования допамин-2-рецепторов | |
| HU184966B (en) | Process for producing phenyl-piperazine derivatives of anti-agression activity | |
| EP0025111B1 (en) | 3-aminopropoxyaryl derivatives, their preparation and pharmaceutical compositions containing them | |
| JPH03181461A (ja) | 抗不整脈剤 | |
| US4148897A (en) | 1,2-Dihydronaphthalene derivatives and pharmaceutical composition | |
| RU2145852C1 (ru) | Ингибитор гипертрофии интимы, применение оксиндолового производного для получения ингибитора гипертрофии интимы, композиция для ингибирования гипертрофии интимы, способ предупреждения и лечения гипертрофии интимы | |
| IE832058L (en) | 1,4-dihydropyridine derivatives | |
| KR850000216B1 (ko) | 피페라진 유도체의 제조방법 | |
| EP0325406B1 (en) | Diamine compounds | |
| JPH0441149B2 (US20030186963A1-20031002-C00002.png) | ||
| US4243666A (en) | 4-Amino-2-piperidino-quinazolines | |
| US5576327A (en) | Treatment of heart rhythym disorders by administration of 3-phenylsulfonyl-3, 7-diazabicyclo[3.3.1]nonane compounds | |
| US4515944A (en) | 1,5-Diphenyl-2-haloalkylpyrazolin-3-one intermediates | |
| US3847923A (en) | N-(1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carbonyloxy)succinimide and glutarimide | |
| CS216525B2 (en) | Method of making the phenylpiperazine derivatives | |
| EP0318029A2 (en) | Cyclic amine and pharmacological composition | |
| EP0270692A1 (en) | Antiarrhythmic agent | |
| AU594840B2 (en) | 1-aryloxy-3-amino-2-propanols | |
| WO1996020179A1 (en) | Piperazine-2,5-dione derivatives as modulators of multi-drug resistance | |
| JPS6130588A (ja) | ベンゾ〔ｃ〕〔１，８〕ナフチリジン、その製造方法及びその使用、並びにこれらの化合物を含有する調製剤 | |
| US4013679A (en) | Substituted 6,7-dihydro [1,7-ab](1) benzazepine compounds | |
| US3963740A (en) | Benzo and benzothiopyranoindazole N-oxides | |
| KR850001038B1 (ko) | 알로파노일 피페라진 화합물의 제조방법 | |
| US4199582A (en) | Piperazine containing dihydronaphthalene derivatives and compositions | |
| RU2128043C1 (ru) | Лекарственные средства для сердечной недостаточности |